Reviews Supplements ECOGS September 2013 : Page 1

(COPE Approved) 2 CE Credits 2013 Highlights EAST COAST OPTOMETRIC GLAUCOMA SYMPOSIUM f ro m t h e l i ve eve n t . ach spring, we gather in Bethesda for the East Coast Optometric Glaucoma Symposium (ECOGS) for a two-day exchange of ideas, techniques and clinical pearls in the management of glaucoma. Our faculty are carefully selected to ensure a comprehensive program addressing new approaches to both the diagnosis and management of glaucoma. This year’s program was the best yet, with education focused on the interpretation of common glaucoma tests such as visual fi elds and optical coherence tomography (OCT), new developments in drug therapy for the reduction of intraocular pressure (IOP) and insight into challenging clinical entities such as pseudoexfoliation and normal-tension glaucoma. In this monograph, which was meticulously compiled by Tony Realini, MD, we have selected a handful of the topics covered at the ECOGS meeting. We hope this timely information has a positive impact on your glaucoma patient outcomes. E — Murray Fingeret, OD, Program Director Release Rel Re R ease D Date: September 2013 Expiration Date: September 30, 2014 Goal Statement: A 2002 report from the National Eye Institute and Prevent Blindness America states that glaucoma affects more than 2.2 million Americans aged 40 and older. This recap of the annual East Coast Optometric Glaucoma Symposium will cover the steps taken to establish the diagnosis of glaucoma, information from the glaucoma clinical trials, risk assessment for ocular hypertension and the relevance of monocular trials and target pressures. Faculty/Editorial Board: Michael Chaglasian, OD; Murray Fingeret, OD; John Flanagan, MCOptom. PhD; I. Ben Gaddie, OD; Tony Realini, MD, MPH Credit Statement: This course is COPE approved for 2 hours of CE credit. COPE ID is 38748-GL. Please check your state licensing board to see if this approval counts toward your CE requirement for relicensure. Joint-Sponsorship Statement: This continuing education course is joint sponsored by the University of Alabama School of Optometry. Disclosure Statement: Dr. Chaglasian is on the advisory boards of Alcon Labs, Allergan Inc., Carl Zeiss Meditec and Sucampo, and serves as a speaker for these companies as well. He also sits on Merck’s advisory board. Dr. Fingeret has no financial relationships to disclose. Dr. Flanagan is a consultant, educator and researcher for Heidelberg Engineering, Carl Zeiss Meditec, Optovue Inc., Alcon, Photon etc. and Thornhill Research and has received honoraria, consulting fees and travel expenses. Dr. Gaddie is a speaker/consultant for Allergan, Alcon, Merck, Carl Zeiss Meditec, Johnson & Johnson, Sucampo Pharmaceuticals, Bausch + Lomb and SarCode. Dr. Realini serves as a consultant to Alcon, Sensimed and Sucampo Pharmaceuticals. He is also a speaker for Lumenis, and has received research equipment. Sponsored by Partially supported by an educational grant from

Next Page

Publication List
Using a screen reader? Click Here